公开(公告)号：US20190218526A1

公开(公告)日：2019-07-18

申请号：US16369177

申请日：2019-03-29

申请人： The Government of the United States of America, as represented by the Secretary of Homeland Security

发明人： Michael Puckette ,  Max V. Rasmussen

IPC分类号： C12N7/00 ,  C07K14/005 ,  G01N33/68 ,  G01N33/569 ,  A61K39/12 ,  C07K16/10 ,  A61K39/135 ,  C12N9/50 ,  A61P31/14 ,  G01N33/573

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/135 ,  A61P31/14 ,  C07K14/005 ,  C07K16/1009 ,  C12N9/506 ,  C12N2770/32122 ,  C12N2770/32123 ,  C12N2770/32134 ,  C12N2770/32151 ,  C12Y304/22028 ,  G01N33/56972 ,  G01N33/56983 ,  G01N33/573 ,  G01N33/6854 ,  G01N2333/09 ,  G01N2333/9513

摘要： This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

公开(公告)号：US20160223529A1

公开(公告)日：2016-08-04

申请号：US15021494

申请日：2014-09-12

申请人： The University of Queensland

发明人： Viktor Stein ,  Kirill Alexandrov

IPC分类号： G01N33/542 ,  C07K14/47 ,  C07K14/005 ,  C12N7/00 ,  C12N9/90 ,  G01N33/58 ,  C07K16/00 ,  C12N9/50 ,  C07K14/00

CPC分类号： G01N33/542 ,  C07K14/00 ,  C07K14/005 ,  C07K14/4728 ,  C07K16/00 ,  C07K19/00 ,  C07K2319/50 ,  C07K2319/61 ,  C07K2319/70 ,  C12N7/00 ,  C12N9/48 ,  C12N9/506 ,  C12N9/90 ,  C12N2770/34011 ,  C12Y304/22044 ,  C12Y502/01008 ,  G01N33/582 ,  G01N2333/08 ,  G01N2333/185 ,  G01N2333/4727 ,  G01N2333/9513

摘要： A biosensor comprises first and second molecular components and is capable of displaying protease activity in response to a binding event mediated by first and second binding partners of the biosensor. The first and second binding partners may bind each other directly or may both bind a target molecule. At least the first molecular component comprises an autoinhibited protease, whereby the binding event switches the protease frora an autoinhibited inactive state to a protease active state. The second molecular component may activate the protease of the first molecular component by binding a cross-binder which releases the autoinhibitor or by cleaving a linker which releases the autoinhibitor. The first and second molecular components may both have autoinhibited proteases which reciprocally activate each other.

摘要翻译： 生物传感器包含第一和第二分子组分，并且能够响应由生物传感器的第一和第二结合伴侣介导的结合事件而显示蛋白酶活性。 第一和第二结合配偶体可以直接结合或可以结合靶分子。 至少第一分子组分包含自身抑制蛋白酶，由此结合事件将蛋白酶frora自动抑制无活性状态切换至蛋白酶活性状态。 第二分子组分可以通过结合释放自身抑制剂的交叉粘合剂或通过切割释放自身抑制剂的接头来活化第一分子组分的蛋白酶。 第一和第二分子组分都可以具有彼此相互激活的自我抑制的蛋白酶。

公开(公告)号：US08889848B2

公开(公告)日：2014-11-18

申请号：US13542551

申请日：2012-07-05

申请人： William E. Delaney, IV ,  Guofeng Cheng ,  Hongmei Mo ,  Simin Xu ,  Mei Yu ,  Amoreena Corsa

发明人： William E. Delaney, IV ,  Guofeng Cheng ,  Hongmei Mo ,  Simin Xu ,  Mei Yu ,  Amoreena Corsa

IPC分类号： C12Q1/70 ,  C12Q1/66 ,  C12N15/86 ,  C12N5/10 ,  C12N5/071 ,  C07K14/005 ,  C12Q1/68 ,  C12N15/64 ,  C12N15/65

CPC分类号： C07K14/005 ,  C12N15/86 ,  C12N2770/24222 ,  C12N2770/24231 ,  C12N2770/24243 ,  C12Q1/707 ,  G01N2333/186 ,  G01N2333/9513 ,  G01N2500/00

摘要： Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.

摘要翻译： 提供丙型肝炎病毒（HCV）基因型3的复制品。 这些复制子包含适应性突变，导致HCV在体外复制的能力。 还提供了制备基因型3复制子的方法和使用这些复制子筛选抗病毒剂的方法。

公开(公告)号：US20120071344A1

公开(公告)日：2012-03-22

申请号：US13239199

申请日：2011-09-21

申请人： Roland WOLKOWICZ

发明人： Roland WOLKOWICZ

IPC分类号： C40B30/04 ,  C40B40/00 ,  C07K19/00 ,  C40B40/10 ,  C40B30/00 ,  C12N15/11

CPC分类号： C12Q1/37 ,  C07K14/005 ,  C07K14/39 ,  C07K14/43595 ,  C07K14/70517 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/04 ,  C07K2319/40 ,  C07K2319/43 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12Q1/18 ,  C12Q1/6897 ,  G01N2333/16 ,  G01N2333/185 ,  G01N2333/186 ,  G01N2333/9513

摘要： The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

摘要翻译： 本发明涉及组合物，例如基于细胞的多重平台以筛选抑制酶的小分子药物，例如蛋白酶，例如病毒蛋白酶，例如HIV蛋白酶; 以及制备和使用这些组合物的方法。 本发明提供了用于鉴定可抑制蛋白酶例如HIV蛋白酶等病毒蛋白酶的组合物例如药物分子的组合物和方法。 在替代实施方案中，本发明提供基于细胞的平台或测定法，以筛选抑制或改变酶活性的组合物，例如小分子或药物，例如参与HIV包膜蛋白加工的钙依赖性蛋白质转化酶，包括切割 HIV gp160信封前体，导致gp120和gp41信封产品。 在一个实施方案中，本发明提供了用于监测酶（例如蛋白酶例如病毒蛋白酶）的活性的基于细胞或复用的平台。

公开(公告)号：US11935657B2

公开(公告)日：2024-03-19

申请号：US17408698

申请日：2021-08-23

申请人： Reliant Immune Diagnostics, Inc.

发明人： Jovan Hutton Pulitzer ,  Henry Joseph Legere, III

IPC分类号： G06K9/00 ,  G01N33/53 ,  G01N33/543 ,  G06Q30/0251 ,  G06T7/00 ,  G16H10/65 ,  G16H50/30 ,  H04N23/60 ,  G06F3/0482

CPC分类号： G16H50/30 ,  G01N33/5302 ,  G01N33/54388 ,  G01N33/54389 ,  G01N33/54391 ,  G06Q30/0267 ,  G06Q30/0269 ,  G06T7/0014 ,  G16H10/65 ,  H04N23/64 ,  G01N2333/59 ,  G01N2333/9513 ,  G06F3/0482 ,  G06F2218/00

摘要： A system and method are provided for collection and testing of a biologic sample. The system and method comprise collecting by a user of a testing device a biologic sample for use with the testing device, assigning correlative values as test results, and receiving the test results at a server disposed on a network. Some aspects further include presenting advertisements and other messages to users through a mobile application operating on a mobile device. These aspects take into account the results of the self-diagnostic test and present different advertisements to the user based on the results of the test.

公开(公告)号：US20190218525A1

公开(公告)日：2019-07-18

申请号：US16368146

申请日：2019-03-28

申请人： The Government of the United States of America, as represented by the Secretary of Homeland Security

发明人： Michael Puckette ,  Max V. Rasmussen

IPC分类号： C12N7/00 ,  C07K14/005 ,  G01N33/68 ,  G01N33/569 ,  A61K39/12 ,  C07K16/10 ,  A61K39/135 ,  C12N9/50 ,  A61P31/14 ,  G01N33/573

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/135 ,  A61P31/14 ,  C07K14/005 ,  C07K16/1009 ,  C12N9/506 ,  C12N2770/32122 ,  C12N2770/32123 ,  C12N2770/32134 ,  C12N2770/32151 ,  C12Y304/22028 ,  G01N33/56972 ,  G01N33/56983 ,  G01N33/573 ,  G01N33/6854 ,  G01N2333/09 ,  G01N2333/9513

摘要： This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P 1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

公开(公告)号：US20180066235A1

公开(公告)日：2018-03-08

申请号：US15259409

申请日：2016-09-08

申请人： The Government of the United States of America, as represented by the Secretary of Homeland Security

发明人： Michael Puckette ,  Max V. Rasmussen

IPC分类号： C12N7/00 ,  A61K39/135 ,  C07K14/005 ,  C12N9/50 ,  G01N33/569 ,  G01N33/68

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/135 ,  A61P31/14 ,  C07K14/005 ,  C07K16/1009 ,  C12N9/506 ,  C12N2770/32122 ,  C12N2770/32123 ,  C12N2770/32134 ,  C12N2770/32151 ,  C12Y304/22028 ,  G01N33/56972 ,  G01N33/56983 ,  G01N33/573 ,  G01N33/6854 ,  G01N2333/09 ,  G01N2333/9513

摘要： This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

公开(公告)号：US20170159102A1

公开(公告)日：2017-06-08

申请号：US15169215

申请日：2016-05-31

申请人： San Diego State University (SDSU) Foudation, dba San Diego State University Research Foundation

发明人： Roland Wolkowicz

IPC分类号： C12Q1/37

CPC分类号： C12Q1/37 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/03 ,  C12N9/506 ,  C12N2503/02 ,  C12N2510/00 ,  C12Y304/23016 ,  G01N33/5076 ,  G01N2333/9513 ,  G01N2500/02 ,  G01N2500/10

摘要： The invention is directed to compositions to screen for small molecule drugs that inhibit proteases, such as viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., HIV proteases. In alternative embodiments, the invention provides cell-based assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelop protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products.

公开(公告)号：US20160083775A1

公开(公告)日：2016-03-24

申请号：US14838283

申请日：2015-08-27

申请人： San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation

发明人： Roland WOLKOWICZ

IPC分类号： C12Q1/37 ,  C07K14/39 ,  C12N7/00 ,  C07K14/435 ,  C12Q1/68 ,  C07K14/705 ,  C07K14/005

CPC分类号： C12Q1/37 ,  C07K14/005 ,  C07K14/39 ,  C07K14/43595 ,  C07K14/70517 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/04 ,  C07K2319/40 ,  C07K2319/43 ,  C07K2319/50 ,  C12N7/00 ,  C12N2740/16022 ,  C12Q1/18 ,  C12Q1/6897 ,  G01N2333/16 ,  G01N2333/185 ,  G01N2333/186 ,  G01N2333/9513

摘要： The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

摘要翻译： 本发明涉及组合物，例如基于细胞的多重平台以筛选抑制酶的小分子药物，例如蛋白酶，例如病毒蛋白酶，例如HIV蛋白酶; 以及制备和使用这些组合物的方法。 本发明提供了用于鉴定可抑制蛋白酶例如HIV蛋白酶等病毒蛋白酶的组合物例如药物分子的组合物和方法。 在替代实施方案中，本发明提供基于细胞的平台或测定法，以筛选抑制或改变酶活性的组合物，例如小分子或药物，例如参与HIV包膜蛋白加工的钙依赖性蛋白质转化酶，包括切割 HIV gp160信封前体，导致gp120和gp41信封产品。 在一个实施方案中，本发明提供了用于监测酶（例如蛋白酶例如病毒蛋白酶）的活性的基于细胞或复用的平台。

公开(公告)号：US20240011107A1

公开(公告)日：2024-01-11

申请号：US18035021

申请日：2021-11-12

申请人： Regents of the University of Minnesota

发明人： Reuben S. Harris ,  Seyed Arad Moghadasi ,  Jordan Becker

IPC分类号： C12Q1/6897 ,  C12Q1/37

CPC分类号： C12Q1/6897 ,  C12Q1/37 ,  G01N2333/8107 ,  G01N2333/9513

摘要： Materials and methods for identifying inhibitors of protease activity are provided herein. For example, this document provides materials and methods that can be used to identify inhibitors of a protease (e.g., SARS-CoV-2 Mpro).